TAGRISSO RECEIVES FULL APPROVAL IN THE EU
25 April 2017 13:30 BST TAGRISSO RECEIVES FULL APPROVAL IN THE EU Full approval follows Tagrisso's expedited Conditional Marketing Authorisation as first-in-class medicine for patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer Tagrisso is a potential new standard of care in 2nd line and subsequent therapy in this hard-to-treat form of lung cancer Approval is based on Phase III AURA3 data which demonstrate significant clinical superiority of Tagrisso over chemotherapy in EGFR T790M mutation-positive NSCLC patients, including those